CEL-SCI Co. (NYSE:CVM) Short Interest Update

Key Points

• CEL-SCI Co. experienced a significant increase in short interest, growing by 36.7% in August, with approximately 15.3% of shares short sold.
• CEO Geert R. Kersten increased his ownership of the company by 66.91% after purchasing 29,197 shares valued at nearly $200,000.
• Bank of America Corp DE drastically raised its stake in CEL-SCI by 2,188.2%, now owning approximately 0.60% of the company with a value of $94,000.

CEL-SCI Co. (NYSE:CVM - Get Free Report) was the target of a significant growth in short interest in the month of August. As of August 15th, there was short interest totaling 1,040,000 shares, a growth of 36.7% from the July 31st total of 760,700 shares. Based on an average trading volume of 804,500 shares, the days-to-cover ratio is currently 1.3 days. Approximately 15.3% of the shares of the stock are short sold. Approximately 15.3% of the shares of the stock are short sold. Based on an average trading volume of 804,500 shares, the days-to-cover ratio is currently 1.3 days.

Analyst Ratings Changes

Separately, Wall Street Zen began coverage on shares of CEL-SCI in a research note on Friday, May 16th. They set a "sell" rating on the stock.

CEL-SCI Price Performance

CEL-SCI stock traded up $0.42 during mid-day trading on Friday, hitting $10.25. The company's stock had a trading volume of 95,083 shares, compared to its average volume of 366,905. The company has a quick ratio of 1.09, a current ratio of 1.07 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $70.54 million, a P/E ratio of -21.35 and a beta of 0.54. CEL-SCI has a twelve month low of $1.98 and a twelve month high of $39.30. The stock's fifty day moving average price is $7.93 and its two-hundred day moving average price is $6.67.

Insider Activity at CEL-SCI

In related news, CEO Geert R. Kersten acquired 29,197 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were acquired at an average price of $6.85 per share, for a total transaction of $199,999.45. Following the completion of the purchase, the chief executive officer directly owned 72,835 shares of the company's stock, valued at $498,919.75. The trade was a 66.91% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 9.93% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CEL-SCI stock. MAI Capital Management boosted its holdings in CEL-SCI Co. (NYSE:CVM - Free Report) by 229.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 526,480 shares of the company's stock after buying an additional 366,880 shares during the quarter. MAI Capital Management owned 0.63% of CEL-SCI worth $121,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 12.08% of the company's stock.

About CEL-SCI

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.